Palisade Bio (PALI) Expected to Announce Earnings on Monday

Key Points

• Earnings scheduled May 11 after market close: Palisade Bio will report Q1 2026 results on Monday, May 11 (earnings call 4:00 PM ET) with analysts forecasting EPS of ($0.04) per share.
• Current stock snapshot: PALI traded up 1.3% to $2.02 on Monday with 283,209 shares changing hands versus an average volume of ~4.35M, a market cap of $337.35M, a 52-week range of $0.53–$2.86, and a negative P/E.
• Analyst and investor sentiment: Ratings are mixed but skew toward bullish—MarketBeat shows an average rating of "Moderate Buy" with a consensus target price of $10.20 while institutional ownership is about 11.8%.

Palisade Bio (NASDAQ:PALI - Get Free Report) is projected to release its Q1 2026 results after the market closes on Monday, May 11th. Analysts expect Palisade Bio to post earnings of ($0.04) per share for the quarter. Individuals may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Monday, May 11, 2026 at 4:00 PM ET.

Palisade Bio Stock Up 1.3%

Shares of NASDAQ PALI traded up $0.03 during trading on Monday, reaching $2.02. 283,209 shares of the company traded hands, compared to its average volume of 4,353,936. The firm has a 50 day simple moving average of $1.96 and a 200-day simple moving average of $1.92. The stock has a market capitalization of $337.35 million, a PE ratio of -0.95 and a beta of 1.52. Palisade Bio has a 52-week low of $0.53 and a 52-week high of $2.86.

Hedge Funds Weigh In On Palisade Bio

Several institutional investors have recently bought and sold shares of the company. XTX Topco Ltd grew its position in Palisade Bio by 53.8% in the 4th quarter. XTX Topco Ltd now owns 21,669 shares of the company's stock valued at $51,000 after acquiring an additional 7,584 shares in the last quarter. Cetera Investment Advisers acquired a new position in Palisade Bio in the 4th quarter valued at about $25,000. Schonfeld Strategic Advisors LLC acquired a new position in shares of Palisade Bio during the fourth quarter worth about $26,000. Virtu Financial LLC acquired a new position in shares of Palisade Bio during the fourth quarter worth about $28,000. Finally, Atom Investors LP acquired a new position in shares of Palisade Bio during the fourth quarter worth about $33,000. 11.79% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on PALI shares. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Palisade Bio in a report on Thursday, January 22nd. Wolfe Research began coverage on shares of Palisade Bio in a report on Thursday, April 9th. They set an "outperform" rating and a $7.00 price target on the stock. Wall Street Zen raised shares of Palisade Bio from a "sell" rating to a "hold" rating in a report on Saturday, February 28th. B. Riley Financial began coverage on shares of Palisade Bio in a report on Friday, January 9th. They issued a "buy" rating and a $7.00 price target on the stock. Finally, Stifel Nicolaus assumed coverage on shares of Palisade Bio in a report on Wednesday, February 25th. They issued a "buy" rating and a $5.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $10.20.

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.